Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin for Delirium Prevention in Critically Ill Patients (MELLOW-1)
NCT02615340Phase 2Unknown
- Sponsor
- Mount Sinai Hospital
- Start
- Oct 2017
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of melatonin in delirium, sponsored by Mount Sinai Hospital. Status: unknown.
02
Drugs
melatonin
03
Conditions
delirium
Beyond the preview
Go deeper on NCT02615340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02615340.